T1	Condition 111 141	esophagogastric adenocarcinoma
T2	Condition 127 141;42 49	adenocarcinoma gastric
*	OR T1 T2
T3	Qualifier 25 41	locally advanced
T4	Scope 42 141	gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma
R1	Has_qualifier Arg1:T4 Arg2:T3	
T5	Qualifier 90 106	mid-body stomach
T6	Qualifier 77 85;99 106	proximal stomach
*	OR T5 T6
T7	Scope 77 106	proximal and mid-body stomach
R2	Has_scope Arg1:T2 Arg2:T7	
T8	Condition 167 182	adenocarcinomas
T9	Qualifier 143 157	distal gastric
T10	Qualifier 159 165	antral
R3	Subsumes Arg1:T9 Arg2:T10	
R4	Has_qualifier Arg1:T8 Arg2:T9	
*	OR T4 T8
T11	Non-query-able 183 258	are eligible for enrolment but will not be included in the primary analysis
T12	Condition 277 284	disease
T13	Qualifier 260 276	Locally advanced
R5	Has_qualifier Arg1:T12 Arg2:T13	
T14	Procedure 302 323	endoscopic ultrasound
T15	Value 336 428	> primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)
R6	Has_value Arg1:T14 Arg2:T15	
R7	AND Arg1:T12 Arg2:T14	
T16	Procedure 325 328	EUS
R8	Subsumes Arg1:T14 Arg2:T16	
T17	Procedure 464 475	laparoscopy
T18	Qualifier 453 463	diagnostic
R9	Has_qualifier Arg1:T17 Arg2:T18	
T19	Procedure 492 513	washings for cytology
T20	Measurement 520 528	cytology
T21	Value 529 537	positive
T22	Value 542 550	negative
*	OR T21 T22
T23	Scope 529 550	positive and negative
R10	Has_scope Arg1:T20 Arg2:T23	
T24	Non-query-able 593 706	nly cytology negative patients will be included in the primary analyses; gross peritoneal disease is not eligible
T25	Measurement 708 742;750 768	Eastern Cooperative Oncology Group performance status
T26	Value 769 773	=< 1
T27	Measurement 744 748	ECOG
R11	Subsumes Arg1:T25 Arg2:T27	
R12	Has_value Arg1:T25 Arg2:T26	
T28	Procedure 788 795	surgery
T29	Qualifier 801 809	curative
R13	Has_qualifier Arg1:T28 Arg2:T29	
T30	Measurement 818 843	Absolute neutrophil count
T31	Measurement 845 848	ANC
T32	Value 850 860	>= 1250/ul
R14	Subsumes Arg1:T30 Arg2:T31	
R15	Has_value Arg1:T30 Arg2:T32	
T33	Measurement 862 872	Hemoglobin
T34	Value 873 882	>= 9 g/dL
R16	Has_value Arg1:T33 Arg2:T34	
T35	Measurement 884 893	Platelets
T36	Value 894 907	>= 100,000/ul
R17	Has_value Arg1:T35 Arg2:T36	
T37	Measurement 909 924	Total bilirubin
T38	Value 925 954	< 1.5 x upper limit of normal
R18	Has_value Arg1:T37 Arg2:T38	
T39	Measurement 956 995	Serum glutamic oxaloacetic transaminase
T40	Measurement 997 1001	SGOT
T41	Measurement 1007 1044	serum glutamate pyruvate transaminase
T42	Measurement 1046 1050	SGPT
T43	Value 1052 1081	< 2.5 x upper limit of normal
T44	Negation 1095 1102	without
T45	Condition 1103 1119	liver metastases
T46	Measurement 1123 1127	SGOT
T47	Measurement 1132 1136	SGPT
T48	Value 1137 1164	< 5 x upper limit of normal
T49	Condition 1183 1199	liver metastases
R19	Subsumes Arg1:T39 Arg2:T40	
R20	Subsumes Arg1:T41 Arg2:T42	
T50	Scope 956 1051	Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT)
R21	Has_value Arg1:T50 Arg2:T43	
R22	Has_negation Arg1:T45 Arg2:T44	
R23	Has_scope Arg1:T45 Arg2:T50	
T51	Scope 1123 1136	SGOT and SGPT
R24	Has_value Arg1:T51 Arg2:T48	
R25	Has_scope Arg1:T49 Arg2:T51	
T52	Measurement 1201 1211	Creatinine
T53	Value 1212 1242	=< 1.5 x upper limit of normal
R26	Has_value Arg1:T52 Arg2:T53	
T54	Measurement 1284 1327	Response Evaluation Criteria in Solid Tumor
T55	Measurement 1329 1335	RECIST
T56	Value 1337 1340	1.1
R27	Subsumes Arg1:T54 Arg2:T55	
R28	Has_value Arg1:T54 Arg2:T56	
T57	Pregnancy_considerations 1359 1760	omen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately
T58	Non-query-able 1762 2013	Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan
T59	Informed_consent 2015 2038	Signed informed consent
